Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Legend Biotech Corporation LEGN
$69.81
-$0.73 (-1.05%)
На 18:02, 12 мая 2023
-5.46%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
11210525848.00000000
-
week52high
70.15
-
week52low
32.87
-
Revenue
117005000
-
P/E TTM
-44
-
Beta
-0.07823000
-
EPS
-2.68000000
-
Last Dividend
0.00000000
-
Next Earnings Date
21 апр 2023 г. в 12:30
Описание компании
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | 15 июл 2022 г. |
| BMO Capital | Outperform | 17 июн 2022 г. | |
| Barclays | Overweight | 15 мар 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 07 мар 2022 г. |
| Morgan Stanley | Overweight | Equal-Weight | 31 янв 2022 г. |
| Morgan Stanley | Overweight | Overweight | 13 окт 2022 г. |
| Evercore ISI Group | Outperform | 02 ноя 2022 г. | |
| Cowen & Co. | Outperform | 01 ноя 2022 г. | |
| Guggenheim | Neutral | 31 окт 2022 г. | |
| Piper Sandler | Overweight | Overweight | 20 дек 2022 г. |
| UBS | Buy | 06 дек 2022 г. | |
| JP Morgan | Overweight | Overweight | 06 дек 2022 г. |
| Barclays | Overweight | Overweight | 25 янв 2023 г. |
| Morgan Stanley | Overweight | Overweight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Legend Biotech: CARTITUDE-4 Study A Success
Seeking Alpha
31 янв 2023 г. в 02:17
Legend Biotech and partner Johnson & Johnson announced positive topline results from the CARTITUDE-4 trial of Carvykti last week. Positive results were expected and the market was not impressed either as no data was mentioned in the press release.
Legend Biotech set for clinical development of potential treatment for small cell lung cancer after FDA approval
Proactive Investors
21 ноя 2022 г. в 10:08
Legend Biotech Corporation (NASDAQ:LEGN) told investors that the US regulator, the Food and Drug Administration (FDA), had green-lighted its investigational new drug (IND) application for the treatment of small cell lung cancer (SCLC). It means the clinical development can now proceed on LB2102, an investigational, antigen receptor T-cell (CAR-T) therapy, in a bid to treat adults with extensive stage SCLC.
Legend Biotech Announces Participation in Upcoming Investor Conferences
Business Wire
04 ноя 2022 г. в 17:00
SOMERSET, N.J.
Legend Biotech: Label Expansions Necessary To Realize Carvykti's Potential
Seeking Alpha
28 окт 2022 г. в 16:26
Legend Bio's Carvykti has been approved and is selling well despite manufacturing issues. Analysts have set multibillion-dollar target peak sales for the product.
Legend Biotech: Carvykti Can Exceed J&J's Peak Sales Guidance
Seeking Alpha
27 окт 2022 г. в 10:54
Legend Biotech's Carvykti was approved this year for the treatment of fourth and fifth-line-plus multiple myeloma. Carvykti is partnered with J&J, and the launch is off to a strong start despite supply challenges, thanks to the outstanding CARTITUDE-1 trial data.